Dr. Andy Clark is CEO of InStatin Inc and a pulmonary development consultant. He helped found the Aerogen Pharma Corporation in 2015 and served as President and Managing Director until 2024. From 2009 to 2014 he was Site Head and Chief Technical Officer for Novartis Pharmaceuticals. Prior to which he was Chief Technical Officer for Nektar Therapeutics and Respira Therapeutics, he also served as Managing Director of Bradford Particle Design. He moved to California in 1992 to lead a pulmonary protein delivery group at Genentech Inc. During this time Andy has made major contributions to some of the industries’ most innovative products; high dose inhaled Chromones (the first high dose pMDI and dry powder inhaler), Pulmozyme (the first inhaled protein), Exubera (the first inhaled systemic protein), TobiPodhaler (the first dry powder inhaled antibiotic). Andy holds a Ph.D. in aerosol science from Loughborough University of Technology, England. In 1993 he was the first recipient of the International Society for Aerosols in Medicine (ISAM) young investigator award, in 2005 he received the Thomas T Mercer award, jointly presented by ISAM and the American Association for Aerosol Research, and in 2012 he received the prestigious Charles G Thiel award awarded by Virginia Commonwealth University (RDD), all awarded for “excellence in pharmaceutical aerosols and inhalable materials”. He served as ISAM president from 2001-2003 and was elected as an ISAM fellow in 2021, at an international conference that he helped organize as congress president.